Deutsch English Français

Contact

EP0827513

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP0827513

EP0827513 - REAGENTS FOR TREATMENT AND DIAGNOSTIC VISUALISATION, PARTICULARLY IN CANCER [Right-click to bookmark this link]
Former [1998/11]	METHODS OF TREATMENT AND DIAGNOSTIC VISUALISATION, PARTICULARLY IN CANCER
	[2006/06]
Status	No opposition filed within time limit Status updated on 15.06.2007 Database last updated on 20.09.2024
Most recent event Tooltip	04.01.2008	Lapse of the patent in a contracting state New state(s): NL	published on 06.02.2008 [2008/06]
Applicant(s)	For all designated states Strahilevitz, Meir P.O.Box 25008 Seattle, WA 98165 / US
	[2006/20]
Former [1998/11]	For all designated states Strahilevitz, Meir P.O.Box 190 Hansville, WA 98340 / US
Inventor(s)	01 / see applicant ...
	[1998/11]
Representative(s)	Schmitz, Jean-Marie, et al Dennemeyer & Associates S.A. P.O. Box 1502 1015 Luxembourg / LU
	[N/P]
Former [1998/11]	Schmitz, Jean-Marie, et al Dennemeyer & Associates Sàrl P.O. Box 1502 1015 Luxembourg / LU
Application number, filing date	96917832.6	24.05.1996
	[1998/11]
	WO1996US07690
Priority number, date	US19950451120	26.05.1995 Original published format: US 451120
	[1998/11]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO9637516
	Date:	28.11.1996
	Language:	EN
	[1996/52]
	Type:	A1 Application with search report
	No.:	EP0827513
	Date:	11.03.1998
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 28.11.1996 takes the place of the publication of the European patent application.
	[1998/11]
	Type:	B1 Patent specification
	No.:	EP0827513
	Date:	09.08.2006
	Language:	EN
	[2006/32]
Search report(s)	International search report - published on:	US	28.11.1996
	(Supplementary) European search report - dispatched on:	EP	18.12.2000
Classification	IPC:	C07K16/46, A61K39/44	[1998/11]
	CPC:	B82Y5/00 (EP,US); A61K47/6893 (EP,US); A61K47/68 (EP,US); A61K47/6891 (EP,US); A61K51/1018 (EP,US); A61K51/1045 (EP,US); (+) A61K9/1271 (EP,US); C07K14/70514 (EP,US); C07K16/1045 (EP,US); C07K16/1292 (EP,US); C07K16/18 (EP,US); C07K16/30 (EP,US); C07K16/3007 (EP,US); C07K16/44 (EP,US); A61K2039/505 (EP,US) (-)
Designated contracting states	CH, DE, ES, FR, GB, IT, LI, NL, SE [1998/11]
Title	German:	REAGENZIEN ZUR BEHANDLUNG UND ZUR DIAGNOSTISCHEN DARSTELLUNG SPEZIELL FÜR KREBS	[2006/06]
	English:	REAGENTS FOR TREATMENT AND DIAGNOSTIC VISUALISATION, PARTICULARLY IN CANCER	[2006/06]
	French:	RÉACTIFS DE TRAITEMENT, DE DIAGNOSTIC ET DE VISUALISATION, NOTAMMENT DE TUMEURS CANCEREUSES	[2006/06]
	Former [1998/11]	VERFAHREN ZUR BEHANDLUNG UND ZUR DIAGNOSTISCHEN DARSTELLUNG SPEZIELL FÜR KREBS
	Former [1998/11]	METHODS OF TREATMENT AND DIAGNOSTIC VISUALISATION, PARTICULARLY IN CANCER
	Former [1998/11]	PROCEDES DE TRAITEMENT, DE DIAGNOSTIC ET DE VISUALISATION, NOTAMMENT DE TUMEURS CANCEREUSES
Entry into regional phase	08.12.1997	National basic fee paid
	08.12.1997	Search fee paid
	08.12.1997	Designation fee(s) paid
	09.12.1997	Examination fee paid
Examination procedure	20.12.1996	Request for preliminary examination filed International Preliminary Examining Authority: US
	09.12.1997	Examination requested [1998/11]
	24.10.2002	Despatch of a communication from the examining division (Time limit: M04)
	19.02.2003	Reply to a communication from the examining division
	01.12.2003	Despatch of a communication from the examining division (Time limit: M06)
	28.05.2004	Reply to a communication from the examining division
	13.06.2005	Despatch of a communication from the examining division (Time limit: M06)
	08.12.2005	Reply to a communication from the examining division
	20.02.2006	Communication of intention to grant the patent
	15.06.2006	Fee for grant paid
	15.06.2006	Fee for publishing/printing paid
Opposition(s)	10.05.2007	No opposition filed within time limit [2007/29]
Fees paid	Renewal fee
	08.12.1997	Renewal fee patent year 03
	21.05.1999	Renewal fee patent year 04
	21.04.2000	Renewal fee patent year 05
	18.05.2001	Renewal fee patent year 06
	24.07.2002	Renewal fee patent year 07
	23.04.2003	Renewal fee patent year 08
	27.05.2004	Renewal fee patent year 09
	19.05.2005	Renewal fee patent year 10
	30.05.2006	Renewal fee patent year 11
	Penalty fee
	Additional fee for renewal fee
	31.05.2002	07 M06 Fee paid on 24.07.2002
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	NL	09.08.2006
	SE	09.11.2006
	ES	20.11.2006
	[2007/21]
Former [2007/16]	SE	09.11.2006
	ES	20.11.2006
Documents cited:	Search	[DA]WO9503084 (STRAHILEVITZ MEIR [US]) [DA] * the whole document *;
		[X] - IMRAN AHMAD ET AL, "ANTIBODY-TARGETED DELIVERY OF DOXORUBICIN ENTRAPPED IN STERICALLY STABILIZED LIPOSOMES CAN ERADICATE LUNG CANCER IN MICE", CANCER RESEARCH,US,AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, (19930401), vol. 53, no. 7, ISSN 0008-5472, pages 1484 - 1488, XP000371716 [X] 1-4,10 * abstract * * page 1484, column 1, line 1 - column 2, line 8 *
		[X] - ALLEN T M ET AL, "ANTIBODY-MEDIATED TARGETING OF LONG-CIRCULATING (STEALTH R) LIPOSOMES", JOURNAL OF LIPOSOME RESEARCH,US,MARCEL DEKKER, NEW YORK, (19940301), vol. 4, no. 1, ISSN 0898-2104, pages 1 - 25, XP000450210 [X] 1-4,10 * abstract * * page 3, line 1 - page 5, paragraph 2 *
	International search	[Y]EP0302673 (BECTON DICKINSON CO [US]);
		[Y]EP0349127 (BIOMEMBRANE INST [US]);
		[YP]WO9515770 (NEORX CORP [US]);
		[YP]US5474772 (MADDOCK STEPHEN W [US]);
		[Y] - WEINSTEIN J.N., "Target-Direction of Liposomes: Four Strategies for Attacking Tumor Cells", UCLA SYMPOSIUM MOLECULAR AND CELLULAR BIOLOGY, RATIONAL BASIS FOR CHEMOTHERAPY, (1983), pages 441 - 473
		[Y] - JONES M A, ET AL., "PREPARATION AND CHARACTERIZATION OF LIGAND-MODIFIED LABELLED LIPOSOMES FOR SOLID PHASE IMMUNOASSAYS", JOURNAL OF LIPOSOME RESEARCH., TAYLOR & FRANCIS, PHILADELPHIA, PA., US, US, (19930101), vol. 03, no. 03, ISSN 0898-2104, pages 793 - 804, XP002940798
		[Y] - LESERMAN L D, ET AL., "TARGETING TO CELLS OF FLUORESCENT LIPOSOMES COVALENTLY COUPLED WITHMONOCLONAL ANTIBODY OR PROTEIN A", NATURE, Nature Publishing Group, United Kingdom, United Kingdom, (19801211), vol. 288, doi:10.1038/288602a0, ISSN 0028-0836, pages 602 - 604, XP002940799 DOI: http://dx.doi.org/10.1038/288602a0
		[X] - FLASHER D., ET AL., "LIPOSOME TARGETING TO HUMAN IMMUNODEFICIENCY VIRUS TYPE 1-INFECTED CELLS VIA RECOMBINANT SOLUBLE CD4 AND CD4 IMMUNOADHESIN (CD4-IGG).", BIOCHIMICA ET BIOPHYSICA ACTA., ELSEVIER, NL, NL, (19940101), vol. 1194., doi:10.1016/0005-2736(94)90219-4, ISSN 0006-3002, pages 185 - 196., XP000569129 DOI: http://dx.doi.org/10.1016/0005-2736(94)90219-4
		[Y] - FANGER M W, SEGAL D M, WUNDERLICH J R, "GOING BOTH WAYS: BISPECIFIC ANTIBODIES AND TARGETED CELLULAR CYTOTOXICITY", The FASEB Journal, Federation of American Societies for Experimental Biology, US, US, (19900801), vol. 04, ISSN 0892-6638, pages 2846 - 2849, XP002940800

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p